Euglena Co., Ltd.

Equities

2931

JP3944370000

Food Processing

Market Closed - Japan Exchange 02:00:00 2024-04-26 am EDT 5-day change 1st Jan Change
524 JPY +3.15% Intraday chart for Euglena Co., Ltd. +2.75% -24.82%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Seiichiro Kametani agreed to acquire Hako inc. from Euglena Co., Ltd. for ¥600 million. CI
Japanese Shares Track Other Asia Stocks Lower Despite China's Rate Cut MT
Euglena Slightly Narrows 2023 Attributable Loss as Net Sales Grow MT
Zenhoren Co.,Ltd. agreed to acquire 18.93% stake in Okinawa Basketball Co., Ltd from Euglena Co., Ltd. for ¥360 million. CI
KAICO, Ltd. announced that it has received ¥810 million in funding from a group of investors CI
Euglena Co., Ltd. agreed to acquire Saticine Medical Co., Ltd. CI
Euglena Co., Ltd. agreed to acquire Japan Beautech Co., Ltd. from Kirei Sozo Holdings, K.K. CI
Euglena Co., Ltd. entered into stock transfer agreement to acquire Nayuta Co., Ltd. from Kirei Sozo Holdings, K.K. and Hiroji Yamazaki for ¥0.0 million. CI
Euglena Widens Attributable Loss in Nine Month MT
Japanese Shares Extend Gains for Sixth Straight Trading Session; Euglena Rises 3% MT
Euglena Opens Call for Chief Future Officers Under 18 Years Old MT
Euglena Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Euglena Sees Attributable Loss Fall in FY22 MT
Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending Dec. 31, 2023 CI
Euglena Co., Ltd. announced that it has received ¥7.7999475 billion in funding from Marui Group Co., Ltd., Rohto Pharmaceutical Co.,Ltd., Mazda Motor Corporation, Dai-ichi Life Holdings, Inc. CI
Euglena Co., Ltd. announced that it expects to receive ¥7.7999475 billion in funding from Marui Group Co., Ltd., Rohto Pharmaceutical Co.,Ltd., Mazda Motor Corporation, Dai-ichi Life Holdings, Inc. CI
Japanese shares end lower on Fed rate hike worries RE
Japan's Nikkei inch lower on worries over Fed rate hike impact RE
Italy's Eni eyes biorefinery in Malaysia with Petronas, Euglena RE
Eni, Euglena, Petronas To Jointly Explore Biorefinery Development In Malaysia MT
Euglena's Attributable Loss Widens in January-September Period MT
Euglena Co., Ltd. Provides Consolidated Financial Guidance for the Year Ending December 31, 2022 CI
Euglena’s H1 Loss Widens; Net Sales Soar 179% MT
Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022 CI
Euglena Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending December 31, 2022 CI
Chart Euglena Co., Ltd.
More charts
euglena Co., Ltd. is a Japan-based company mainly engaged in the healthcare, energy and environmental business utilizing the research and development results on euglena. The Company masters the core technology of euglena, which provides the edibility of microalga euglena (Japanese name: Midorimushi) and the technology of outdoor large-scale cultivation. The Company operates in two business segments. The Healthcare segment is involved in the original equipment manufacturer (OEM) provision of food and cosmetics using euglena, as well as the planning and sale of products. The Energy and Environment segment is involved in the technology development and commissioned research of euglena and other microalgae, as well as the research and development of biofuels for the future commercialization.
More about the company
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
524 JPY
Average target price
1,000 JPY
Spread / Average Target
+90.84%
Consensus
  1. Stock Market
  2. Equities
  3. 2931 Stock
  4. News Euglena Co., Ltd.
  5. Euglena Slightly Narrows 2023 Attributable Loss as Net Sales Grow